GCM
SRPT icon

Graham Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Graham Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$561K Buy
31,192
+8,750
+39% +$165K 0.01% 672
2026
Q1 		$488K Buy
+22,442
New +$434K 0.01% 631
2024
Q4 		– Sell
-5,732
Closed -$716K – 1466
2024
Q3 		$716K Buy
+5,732
New +$792K 0.01% 546
2022
Q4 		– Sell
-20,908
Closed -$2.31M – 1326
2022
Q3 		$2.31M Sell
20,908
-2,163
-9% -$218K 0.09% 184
2022
Q2 		$1.73M Buy
+23,071
New +$1.7M 0.07% 249

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Graham Capital Management's SRPT Position: Q2 2026 in Review

Graham Capital Management increased its Sarepta Therapeutics (SRPT) stake by 39% in Q2 2026, buying an estimated $165K and bringing the position to 31,192 shares worth $561K. The position accounts for 0.01% of the portfolio, ranked #672.

Graham Capital Management first reported a position in SRPT in Q2 2022 and has held it in 5 quarters since. The position peaked at $2.31M in Q3 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Graham Capital Management held 31,192 shares of Sarepta Therapeutics worth $561K as of Q2 2026.
  • Graham Capital Management bought 8,750 Sarepta Therapeutics shares in Q2 2026, an estimated $165K.
  • Sarepta Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #672 holding.
  • Graham Capital Management first reported a position in Sarepta Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • Graham Capital Management's Sarepta Therapeutics position peaked at $2.31M in Q3 2022.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.